Coralville-based Integrated DNA Technologies, a global leader in genomics solutions, has joined forces with Elegen, a leader in next-generation DNA manufacturing, to provide researchers with early access to complex gene synthesis.
The partnership grants IDT customers early access to Elegen’s ENFINIA Plasmid DNA, a service that delivers high-complexity clonal gene synthesis ranging from 5 kb to 15 kb in as little as 10 business days.
According to a release, this collaboration enhances IDT’s synthetic biology portfolio, which includes gene fragments, Rapid Genes, and various vector and plate formats designed for high-throughput workflows. Customers will now have a cost-effective solution for obtaining NGS-verified clonal genes, shipped directly from Elegen’s U.S. facility.
“IDT has continued to bolster its synthetic biology offerings and capabilities with new products and enhancements, as well as a U.S. facility expansion, to boost our throughput and efficiency over the last 12 months,” said Sandy Ottensmann, vice president and general manager of IDT’s Gene Writing & Editing Business Unit. “Our partnership with Elegen allows us to offer customers competitively priced long and complex DNA that they can pair with IDT’s extensive portfolio of custom synthetic biology solutions.”
“We are thrilled to partner with IDT, a long-standing leader in DNA synthesis,” said Elegen’s founder and CEO, Matthew Hill. “This collaboration allows Elegen to expand access to our ENFINIA Plasmid DNA and equip researchers rapid access to longer and more complex DNA sequences – capabilities that have historically been limited in the market. We believe this partnership will accelerate research and development across the industry, driving innovation and breakthroughs in the life sciences.”
The early access program is now available for IDT customers ahead of the full commercial launch. More details can be found at www.idtdna.com/LongDNA.
